

Department of Public Health
Position Statement
CBD Product Availability in Iowa

The Department of Public Health (Department) has received a number of inquiries about the legality of CBD products currently sold in the state of Iowa. It is the position of the Department that CBD products other than those manufactured under the Department's regulatory program are not legal in the state of Iowa. There are three exceptions to this:

1. The following appropriately prescribed, FDA-approved drugs: Marinol, Syndros, Cesamet
2. The following drugs as part of a FDA-approved clinical trial: Sativex and Epidiolex
3. Products with less than 3% THC that are in a form recommended by the Medical Cannabidiol Board, approved by the Board of Medicine and adopted by the Department pursuant to administrative rule. Products that meet this exception do not currently exist, as the required administrative rule has not been adopted. The required administrative rule is anticipated to be adopted in 2018.

Products manufactured in the state under the provisions of Iowa Code chapter 124E will be available at Department licensed dispensaries only, starting in late 2018.

The Department's authority under Iowa Code chapter 124E does not extend to regulation of the sale or use of the types of CBD products which may be currently available at retailers throughout the state. Consumers of these products should be aware that these products have not been approved for use under either a federal or state of Iowa regulatory program. Agencies with enforcement authority in this area include the federal Drug Enforcement Administration, the federal Food and Drug Administration, county attorneys and law enforcement agencies.

For additional information, please contact: Sarah Reisetter, IDPH Deputy Director, sarah.reisetter@idph.iowa.gov, 515-201-0926.